INDIANAPOLIS, June 13, 2020 New real-world data showed Trulicity® (dulaglutide) had significantly higher adherence and longer persistence compared to weekly injections of semaglutide or exenatide (BCise pen) in people with type 2 diabetes new to GLP-1 receptor agonist (RA) treatment.1 Eli Lilly and Company (NYSE: LLY) presented these data today during the American Diabetes Association’s (ADA) 80th Scientific Sessions®.
The real-world study comparing adherence and persistence used U.S. claims data of people with type 2 diabetes initiating weekly injectable treatment with Trulicity, semaglutide or exenatide.1 Matched cohorts were well balanced for characteristics such as age, gender, adapted Diabetes Complications Severity Index (aDCSI) score and select comorbidities.
At six months, people taking Trulicity showed higher adherence and persistence than those taking semaglutide or exenatide. Further, significantly fewer people discontinued treatment with Trulicity compared to semaglutide or exenatide.
Trulicity versus injectable semaglutide:
- Adherence: 59.7 percent (Trulicity) versus 42.7 percent (semaglutide).
- Persistence: 143.6 days (Trulicity) versus 129.9 days (semaglutide).
- Treatment discontinuation: 30.8 percent (Trulicity) versus 40.8 percent (semaglutide).
Trulicity versus exenatide:
- Adherence: 58.1 percent (Trulicity) versus 40.3 percent (exenatide).
- Persistence: 142 days (Trulicity) versus 121.4 days (exenatide).
- Treatment discontinuation: 32.1 percent (Trulicity) versus 49.4 percent (exenatide).
“Type 2 diabetes is a progressive and personal condition and real-world studies are critical to help us further understand people’s experiences with the condition and treatment,” said Leonard Glass, M.D., F.A.C.E., vice president of Medical Affairs, Lilly. “This real-world study reinforces the value of the simple approach of once-weekly Trulicity and the long-term impact it can have on not only the treatment experience of people with diabetes, but also on outcomes.”